Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.

By E. Papini, R. Guglielmi, A. Bianchini, A. Crescenzi, S. Taccogna, F. Nardi, C. Panunzi, R. Rinaldi, V. Toscano, Claudio M Pacella. Journal of Clinical Endocrinology and Metabolism, 2002

1,460 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/c389e5a5642456da2a8dbef0c704a8ab0b60cd50

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Y. Nikiforov
2. M. Nikiforova
3. D. Cooper

In Surgery

1. Y. Nikiforov
2. M. Nikiforova

Citations in the corpus

• Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. (2006, background): “Nodules with prominent central flow have an increased risk of malignancy (23, 27, 41, 42).”
• Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. (2007, background): “Among several US patterns, hypoechogenicity of the nodule, spot microcalcifications, and the absence of halo sign have been useful for predicting thyroid malignancy (14, 15).”
• Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum (2011, background): “The presence of two or more suspicious sonographic criteria reliably identifies most neoplastic lesions of the thyroid gland (87%– 93% of cases) (229).”
• Ultrasonography Diagnosis and Imaging-Based Management of Thyroid Nodules: Revised Korean Society of Thyroid Radiology Consensus Statement and Recommendations (2016, background): “The rate of malignancy was 8–12% of the nonpalpable nodules evaluated by fine-needle aspiration (FNA) (4, 5), and 1.”
• American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. (2006, background): “The risk of cancer is not significantly higher in impalpable solitary thyroid nodules than in MNGs (16); this finding confirms what has been observed in palpable lesions (17,18; grade C).”
• Management of the solitary thyroid nodule. (2008, background): “Previous guidelines had recommended that the decision to perform a fine-needle aspiration biopsy (FNAB) should be based on nodules10mm.Ithasnowbeendemonstratedthatcancer in nodules 10 mm is not less frequent, and if this value is used as a cutoff, then a significant proportion of cancers will be mis”
• Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “[A14] How should multinodular thyroid glands or multinodular goiters be evaluated for malignancy? Patients with multiple thyroid nodules have the same risk of malignancy as those with solitary nodules (18,44).”
• Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce (2006, positive): “Sonographic characteristics are superior to nodule size for identifying nodules that are more likely to be malignant (37,38) and include the presence of microcalcifications, hypoechogenicity (darker than the surrounding thyroid parenchyma) of a solid nodule, and intranodular hypervascularity…”
• Molecular genetics and diagnosis of thyroid cancer (2011, background): “Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a”
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “Two other studies and a meta-analysis with higher proportions of follicular thyroid cancer (FTC) (10%–22%) have shown that intranodular vascularity was correlated with malignancy (66,74,81).”